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Summary 
UraciI-DNA glycosylase inhibitor (Ugi) is a B. subtilis 
bacteriophage protein that protects the uracil-contain- 
ing phage DNA by irreversibly inhibiting the key DNA 
repair enzyme uraciI-DNA glycosylase (UDG). The 1.9 
A crystal structure of Ugi complexed to human UDG 
reveals that the Ugi structure, consisting of a twisted 
five-stranded antiparallel I~ sheet and two a helices, 
binds by inserting a I~ strand into the conserved DNA- 
binding groove of the enzyme without contacting the 
uracil specificity pocket. The resulting interface, 
which buries over 1200 .~,2 on Ugi and involves the en- 
tire ~ sheet and an a helix, is polar and contains 22 
water molecules. Ugi binds the sequence-conserved 
DNA-binding groove of UDG via shape and electro- 
static complementarity, specific charged hydrogen 
bonds, and hydrophobic packing enveloping Leu-272 
from a protruding UDG loop. The apparent mimicry 
by Ugi of DNA interactions with UDG provides both a 
structural mechanism for UDG binding to DNA, includ- 
ing the enzyme-assisted expulsion of uracil from the 
DNA helix, and a crystallographic basis for the design 
of inhibitors with scientific and therapeutic applications. 
Introduction 
Damage to DNA arises continually throughout he cell cy- 
cle and must be recognized and repaired prior to the next 
round of replication to maintain the genomic integrity of 
the cell. DNA base damage can be recognized and excised 
by the ATP-dependent nucleotide excision repair systems 
(Aboussekhra and Wood, 1994) or by the base excision 
repair systems typified by the DNA glycosylases. Uracil- 
DNA glycosylase (UDG) specifically recognizes uracil in 
DNA and initiates base excision repair by hydrolyzing the 
N-C1' glycosylic bond linking the uracil base to the deoxy- 
ribose sugar. This creates an abasic site that is removed by 
a 5'-acting apurinic/apyrimidinic (AP) endonuclease and a 
deoxyribophosphodiesterase, l aving a gap that is filled 
by DNA polymerase and closed by DNA ligase. This base 
excision repair pathway is the major cellular defense 
mechanism against spontaneous DNA damage (Lindahl, 
1994). 
Uracil arises in DNA either through incorporation of 
dUMP in place of dTMP (Tye et al., 1977) or through the 
continuous deamination of cytosine, which can lead to 
GC--*AT transition mutations if left unrepaired (Frederico 
et al., 1990; Duncan and Miller, 1980). In vivo, UDGs spe- 
cifically recognize uracil in DNA and cleave the glycosylic 
bond to initiate the uracil excision repair pathway. In vitro, 
UDGs can recognize and remove uracil from both single- 
stranded DNA (ssDNA) and double-stranded DNA (dsDNA) 
substrates. UDGs are ubiquitous enzymes, conserved 
throughout evolution, with greater than 55% amino acid 
identity between the human and bacterial proteins (Olsen 
et al., 1989; Upton et al., 1993). The crystal structures of 
both the human enzyme (Mol et al., 1995) and the enzyme 
from herpes simplex virus type 1 (HSV-1) (Savva et al., 
1995) have highly conserved active site regions. The archi- 
tecture of the UDG active site suggests that the enzyme 
must bind uracil that is extrahelical, or "flipped out", from 
the DNA base stack. 
The Bacillus subtilis bacteriophages PBS1 and PBS2 
are novel in that their DNA genomes naturally contain ura- 
cil in place of thymine (Takahashi and Marmur, 1963). 
These bacteriophages produce UDG inhibitor (Ugi) pro- 
teins to protect their genomic DNA from host UDG repair 
enzymes. Thus, PBS2 DNA has evolved to contain an 
overall base composition of 72% AU and 28% GC (Taka- 
hashi and Marmur, 1963). The bacteriophage PBS2 ugi 
gene has been cloned and expressed in Escherichia coli 
(Wang and Mosbaugh, 1988). Ugi is an 84 residue 9474 
Da acidic protein (pl 4.2) (Bennett and Mosbaugh, 1992), 
with ~/~ secondary structure as determined by nuclear 
magnetic resonance (NMR) (Balasubramanian et al., 1995). 
Ugi inactivates UDGs from a variety of diverse organisms 
including Micrococcus luteus, Saccharomyces cerevisiae, 
rats, and humans (Wang and Mosbaugh, 1989; Karran et 
al., 1981 ; Cone et al., 1977). Ugi inhibits E. coli UDG (Ung) 
by a two-step mechanism (Bennett et al., 1993): rapid pre- 
equilibrium with a K~ of 1.3 I~M is followed by formation 
of a stable 1:1 complex that is essentially irreversible under 
physiological conditions (Bennett and Mosbaugh, 1992). 
Here, we report inhibition of human UDG by Ugi, as 
well as the human UDG-Ugi complex crystal structure 
determined at 1.9 ~, resolution. The UDG-Ugi interface is 
very polar and buries nearly one quarter of the solvent- 
accessible surface of Ugi, with the two interacting surfaces 
displaying both shape and electrostatic omplementarity. 
Interactions observed at the UDG-Ugi interface suggest 
that Ugi achieves its tight binding to UDG by acting as a 
DNA mimic. This mimicry is most likely specific for a dsDNA 
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substrate containing an AP site created when the uracil 
base flips out of the dsDNA base stack. The apparent 
mimicry by Ugi of DNA interactions with UDG provides a 
structural basis for UDG binding to dsDNA and clarifies 
the roles played by key enzyme residues. 
Results and Discussion 
Inhibition of Human UDG by PBS2 Ugi 
The effect of Ugi on UDG activity was determined by mea- 
suring the amount of uracil released from synthetic dsDNA 
substrates with various amounts of inhibitor present in the 
reaction mixture. Human UDG activity toward uracil-con- 
taining dsDNA was effectively inactivated by Ugi (Figure 
1). The human enzyme was inactivated -3  times more 
efficiently than the E. coli enzyme, since 50% inhibition 
was achieved at Ugi concentrations of 1.2 x 10 ~ M and 
3.6 x 10 -~ M, respectively. This difference did not reflect 
a difference in the amount of active enzyme between the 
two preparations since 740 pmol of both the human and 
E. coli enzymes complexed with the same amount of [3sS] 
Ugi when placed under saturating conditions of inhibitor 
protein, indicating that both samples contained identical 
amounts of complexable enzyme. 
Structure Determination 
The crystal structure of the complex between human UDG 
and the Ugi protein from bacteriophage PBS2 was deter- 
mined using a combination of molecular replacement and 
multiple isomorphous replacement (MIR) methods (Table 
1). The crystals belong to the monoclinic spacegroup P2~ 
(a = 48.3A, b = 64.5,~,, c = 55.2~,, and I~ = 113.8 ° ) 
and contain one UDG-Ugi complex per asymmetric unit. 
The orientation and position of the UDG in the complex 
was determined by molecular eplacement using the struc- 
ture of the uncomplexed enzyme refined at 1.57,~ resolu- 
tion as a model and used to calculate phases that were 
combined with the MIR phases using the program c~A 
(Read, 1986). The oA-weighted combined phases had an 
overall figure of merit of 0.86 for data to 2.5 ,& resolution 
and were used to calculate electron density maps from 
which the structure of Ugi in the complex was traced (see 
Experimental Procedures). 
The human UDG-Ugi complex structure has been re- 
fined at 1.9 ,~ resolution to a crystallographic R value of 
0.197 with reasonable stereochemistry. All 224 residues 
of UDG and residues 3-84 of Ugi are clearly visible in 
2Fo - Fo electron density maps (Figure 2). The UDG in the 
complex is a fully active recombinant protein and is nearly 
identical to the refined high resolution structure of the free 
enzyme (Mol et al., 1995). The root-mean-square (rms) 
deviation between their polypeptide backbone atoms is 
0.47 A,  rising to 1.1 ,~, for all atoms, without any significant 
shifts in the UDG main chain at the UDG-Ugi interface. 
Structure of the PBS2 Ugi Protein 
The Ugi structure in the complex consists of a five- 
stranded antiparallel J3 sheet and two ~ helices that fold 
into a compact disk shape of approximate dimensions 35 
,~, x 35 A x 25 ,~ (Figures 3A and 3B). An N-terminal 
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Figure 1. Inhibition of E. coil and Human UDG by Bacteriophage 
PBS2 Ugi Protein 
Two standard UDG inhibitor eaction mixtures (900 ixl) were prepared 
containing either 9 fmol of E. coli UDG (Ung, closed squares) or 9 
fmol of human UDG (open squares). Aliquots (75 ~.1) of each reaction 
mixture were added to 25 ILl samples of Ugi to contain various amounts 
of inhibitor protein. Each assay mixture, containing 0.07 U of E. coil 
or 0.11 U of human UDG, was incubated for 30 min at 37°C, and the 
amount of [3H]uracil released from calf thymus [uracil-3H]DNA (195 
cpm/pmol) was determined as previously described (Bennett and Mos- 
baugh, 1992; Bennett et al., 1994). E. coli and human UDG con- 
centrations were determined using the molar extinction coefficients 
E280~r~ = 4.22 x 104 and 5.04 x 104, respectively. 
helix, a l  (Ser-15 to Lys-114, residue numbers from Ugi are 
prefixed with the letter I), is followed by the first 13 strand, 
131 (Glu-120 to Met-124), of the five-stranded antiparallel 
sheet, the second ct helix, a2 (Glu-127 to Asn-135), and the 
four remaining strands of the 13 sheet, 1[]2 to 135 (11e-141 to 
Asp-148, Glu-153 to Ser-160, Ala-169 to Asp-174, and Asn-179 
to Leu-184, respectively). The ~ strands have nearest 
neighbor (+1) connectivity and the characteristic right- 
handed twist seen in other protein structures (Richardson 
and Richardson, 1989). The two a helices lie on opposite 
Table 1. Structure Determination of Human UDG-Ugi Complex 
Parameters Native EtHgP a HgaP b 
Concentration [mM] -- 1 1 
Soaking time (hr) - 24 24 
(,~,) 1.08 1.5418 1.5418 Wavelength 
Resolution (A) 1.9 2.5 2.5 
Completeness (%) 93 88 87 
Observations 42,119 21,496 20,184 
Unique reflections 22,406 9,911 9,745 
Rsym c (%) 5.6 4.9 12.2 
R~se d (0/0) -- 23.6 30.3 
Root,t, e -- 0.52 0.65 
Rms Fh/Eid -- 2.06 1.50 
Number of sites -- 3 1 
EtHgP, ethylm ercuriphosphate. 
b Hg3P, mercuric phosphate, Hga(PO4)2. 
c Rsym is the unweighted R value on I between symmetry mates. 
d a,,o = .Y-.(IFderl - IFn~,I)/Z:IFoa, I. 
° Rco,,,s = Z[IF, I - (IFp, I - IFpl)]/~IF, I for centric reflections. 
f Rms Fh/Esso, rms heavy atom F/isomorphous lack of closure error; 
phasing power. 
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Figure 2. A Stereoview Looking at the UDG-Ugi Interface at the Active Site of the Enzyme 
The electron density (pink) is from a 2Fo - Fc map contoured at 1.0a. The map is superimposed on the coordinates of the complex refined at 
1.9 ~, resolution. Residues from the UDG active site (yellow carbon bonds) interact closely with residues from the first Ugi I~ strand (green carbon 
bonds). The red crosses represent bound water molecules. Figure displayed with XtalView (McRee, 1992). 
sides of the sheet roughly perpendicular to the [3 strands 
(Figure 3B). Although the topology of Ugi resembles the 
proteinase inhibitors cystatin (Bode et al., 1988) and stefin 
B (Stubbs et al., 1990), Ugi apparently binds UDG by a 
different recognition mechanism. In the proteinase inhibi- 
tors, the interactions with proteinase are provided by loops 
that extend from the 13 sheet, with the sheet itself oriented 
away from the enzyme. In the UDG-Ugi complex, the resi- 
dues of the Ugi 13 sheet and a2 dominate the interface 
(Figures 3A and 3B). 
The Human UDG-Ugi Interface 
Ugi interacts with conserved U DG active site residues over 
a large interface providing the basis for its tight binding 
and broad biological specificity for UDG enzymes. Ugi in- 
serts [31 into the active site groove (Figure 2) and envelops 
the conserved UDG Leu-272 active site loop (Figure 3A). 
The amino acid distribution at the interface is markedly 
asymmetric (Figures 3B and 3C). Hydrophobic residues 
cluster within a pocket between the Ugi 13 sheet and a2 
and at the conserved, protruding UDG loop, with polar and 
charged amino acids and bound waters lining the interface 
periphery (Figures 3B and 3C). The interface is very polar, 
containing 18 hydrogen bonds, involving 12 enzyme side 
chains and 14 inhibitor side chains. There are 22 ordered 
water molecules, primarily rimming the interface and the 
central uracil recognition pocket, which is not bound by Ugi 
(Figure 4A). The interacting surfaces display electrostatic 
(Figure 4B) and shape (Figure 4A) complementarity. A 
negatively charged ridge on the edge of the Ugi 13 sheet 
nestles into the positively charged active site groove of 
UDG, while the Ugi hydrophobic pocket surrounds the pro- 
truding UDG Leu-272 loop (Figures 4B and 4C). The two- 
step kinetic mechanism for Ugi association with E. coli Ung 
(Bennett et al., 1993) may derive from initial electrostatic 
interactions followed by the specific hydrogen bonding 
and packing interactions that dominate the interface. 
The interface encompasses over 1200 .~2 or nearly one 
quarter of the total Ugi solvent-accessible surface (Figure 
4B); 22 Ugi residues and 22 UDG residues dominate the 
interface and together comprise 93% and 92%, respec- 
tively, of the total buried surface area for each protein 
(see Figures 3B and 3C). The UDG Leu-272 side chain is 
completely exposed in the free enzyme and completely 
buried in the complex (Figure 4C). Near the rim of the Ugi 
leucine-binding pocket, the side chains of three inhibitor 
residues (Asn-154, Gin-173, and Glu-178) establish a hydro- 
gen-bonded network with ordered solvent molecules and 
with the backbone atoms of UDG residues Pro-271 through 
Tyr-275. 
For Ugi, the residues of [31 undergo the most drastic 
change in solvent accessibility upon complex formation. 
Conserved amino acids near the active site of the enzyme 
interact with six sequential Ugi residues (Gin-119 to Met- 
i24; Figure 2). The side chains of conserved glutamine 
residues Gin-144 and Gin-152 form hydrogen bonds with 
the backbone amide and carbonyl groups of Leu-123 and 
the backbone amide of Gin-119, respectively. The His-268 
imidazole packs against the Ile-122 side chain, while Ser- 
121 O~, forms a strong hydrogen bond ( -  2.8 A) with His- 
148 N~2 (Figure 2). The Glu-120 carboxylate forms a pair 
of hydrogen bonds to the Ser-169 backbone amide and 
side chain O~,. The Glu-128 carboxylate, near the N-ter- 
minus of Ugi a2, similarly forms hydrogen bonds to the 
Ser-247 amide and 07. Glu-128 O~1 also forms water- 
mediated hydrogen bonds with the His-268 backbone 
amide and Ser-273 07. Additional interactions observed 
between Ugi and UDG involving nonconserved UDG resi- 
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dues include salt bridges between Asp-161 and Lys-218 
(alanine in E. coil Ung) and between Glu-131 and Arg-276. 
Ugi does not bind directly to residues of the UDG uracil- 
binding pocket (Tyr-147, Phe-158, Asn-204, and the Gin- 
144 and Asp-145 backbone) (Figure 4A). Thus, the tight 
binding of Ugi to UDG does not derive from targeting of 
the exquisite specificity of the enzyme for uracil, but appar- 
ently arises from its ability to functionally mimic substrate 
DNA binding. Several biochemical observations (Bennett 
and Mosbaugh, 1992; Bennett et al., 1994) and mutational 
analysis (Mol et al., 1995) suggest that Ugi binds to UDG 
at the DNA-binding site. First, the UDG-Ugi complex does 
not bind DNA. Second, UV-catalyzed cross-linking of UDG 
to single-stranded oligonucleotide dT20 abolished binding 
of Ugi. Third, the UDG-Ugi complex is refractory to UV 
cross-linking to dT20. Fourth, five single-site UDG mutants 
in the UDG-Ugi interface (Gin-144, Tyr-147, His-148, His- 
268, and Ser-270) all show reduced binding to DNA (Mol 
et al., 1995). Taken together, these results suggest that 
binding of Ugi and DNA to the enzyme are mutually exclu- 
sive and are likely to involve the same enzyme residues. 
Moreover, the complex crystal structure suggests the re- 
markable Ugi inactivation of UDGs from diverse biological 
systems results from Ugi targeting the DNA-binding region 
of UDG. Apparently, Ugi has capitalized on the biologically 
required structural conservation of UDG regions that bind 
DNA, as no selective pressure exists to maintain the integ- 
rity of the Ugi-binding site. Ugi apparently mimics duplex 
DNA interactions with UDG by overall charge and shape 
Figure 3. Structure of the UDG-Ugi Complex Shown as Ribbon Dia- 
grams 
(A) View showing Ugi (top) bound to UDG (bottom). ~1 of the five- 
stranded antiparallel Ugi 13 sheet (orange arrows) inserts into the UDG
active site groove approximately perpendicular to the C-terminal edge 
of the four-stranded parallel UDG 13 sheet (yellow arrows). The se- 
quence-conserved (His-268, Pro-2~9, Ser-270, Pro-271, Leu-272, and 
Ser-273) UDG active site loop (green tube, right) protrudes upward 
into a hydrophobic pocket formed by (~2 (blue coil, right) and the curved 
sheet of Ugi. 
(B) Ugi structure in the complex, shown from the viewpoint of the 
enzyme active site. Side chains of inhibitor residues that interact with 
UDG are labeled (with their one letter amino acid code and residue 
number) and colored according to their chemical nature (negatively 
charged, red; polar, purple; hydrophobic, white), wi h nitrogen (blue), 
oxygen (red), and sulfur (yellow) atoms displayed as spheres. Ugi i- 
dues in the UDG-Ugi interface include the following: Asn-3 (bottom) 
from the N-terminus (N); Ile-18, Gin-19 from the loop (pink tube, lower 
right) between ~1 and 131; all residues (Glu-20, Ser-2t, Ile-22, Leu-23, 
and Met-24) from 131 (yellow arrow, foreground, lower right to upper 
left); Glu-28, Glu-31, and Val-32 from (12 (blue coil, upper left); Thr-45 
from 1~2; Asn-54 and Met-56 from ~3 (central yellow arrow, horizontal); 
Asp-61, Ala-62, and Tyr-65 from the loop between 133and l~4 (pink 
tube, lower left); Gin-73 from ~4;and Gly-77 and Glu-78 from the loop 
between 134 and 135 (pink tube, upper right). 
(C) UDG structure in the complex shown with the active site groove 
and Ugi interface at the top and ~ sheet (yellow arrows) approximately 
on edge (rotated -90 ° around a vertical axis from [A]). The protein 
is colored according to secondary structure with .B sheets (yellow), (~ 
helices (purple), and loop regions (green). Coloring and labeling of 
the amino acid side chains that interact with UDG is as described for 
Ugi with positively charged residues colored blue. Key UDG residues 
in the UDG-Ugi interface include th following: Gin-144, His-148, Gin- 
152, Pro-165, Ser-169, Hie-212, Ala-214, Asn-215, Ser-247, Tyr-248, 
His-268, Leu-272, Tyr-275, and Arg-276. Figure displayed using stan- 
dard and local modules of the AVS graphics system (AVS Incorpo- 
rated, Waltham, Massachusetts). 
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complementarity through charged hydrogen bonds to con- 
served active site residues and by insertion of the protrud- 
ing Leu-272 of UDG into the hydrophobic pocket of Ugi. 
However, Ugi does not inhibit other DNA glycosylases that 
are specific for 3-methyladenine, 2,6-diamino-4-hydroxy- 
5-(N-methylformamido) pyrimidine or hypoxanthine (Kar- 
ran et al., 1981), or other DNA metabolizing enzymes, such 
as E. coli DNA polymerase I, HeLa DNA polymerase c~, 
Novikoff hepatoma DNA polymerase ~, or porcine liver 
DNA polymerase 7, which also recognize DNA (Wang and 
Mosbaugh, 1989). Thus, the DNA mimicry by Ugi is spe- 
cific for the DNA-binding region of UDGs. 
Implications for UDG Recognition of 
Uracil-Containing dsDNA 
These structural results and those from the human (Mol 
et al., 1995) and HSV-1 (Savva et al., 1995) UDG crystal 
structures suggest a specific model for UDG-DNA interac- 
tion. The structure of the human UDG-Ugi  complex high- 
lights conserved residues that are likely to play key roles 
in the in vivo activity of UDG. Glu-120 and Glu-128 appear 
to mimic DNA phosphate groups. Glu-120 interacts with 
the equivalent residues in human UDG that are identified 
as the sulfate- and phosphate-binding sites in the HSV-1 
enzyme (Savva et al., 1995). Assuming Leu-272 pene- 
Figure 4. Solvent-Accessible Surfaces of Human UDG and PBS2 Ugi 
View rotated -90 ° around a horizontal axis from Figure 3A looking 
down into the active site groove of UDG (bottom). The Ugi protein 
(top) has been rotated -180 ° to expose the interacting surface that 
contacts the enzyme. 
(A) The surface is colored according to the buried surface area of the 
UDG-Ugi complex. Residues of UDG that are inaccessible to a 1.6 ,~ 
solvent probe when Ugi binds are colored blue, while the buried resi- 
dues of Ugi are colored red. An area of approximately 1200 ~,2, out 
of a total of 4800 ,~2, of the solvent-accessible surface of Ugi is buried. 
The corresponding buried surface area of UDGin the complex is about 
1275 h? Out of a total surface area of 9880 ,~,2. Solvent molecules that 
occur at the interface (12 buried waters and a further 10 partially buried) 
are shown as red spheres and mapped onto the surface of UDG. The 
yellow area in the center of the UDG buried surface corresponds to 
the uracil-recognition pocket, which is filled with solvent and does not 
interact directly with the inhibitor. 
(B) The surface is colored according to the electrostatic potential (-3 
kT/e to +3 kT/e) with regions of positive potential colored blue, neutral 
white, and negative red. Surface potential w scalculated with the pro- 
gram DELPHI (Biosym Technologies, Incorporated) using AMBER par- 
tial charges at pH 5.0 and an ionic strength of 145 mM and a radius 
of 1.6 ,~ for the solvent, with the solute and solvent dielectric constants 
set to 2.0 and 80.0, respectively~ The side chain of Leu-272 projects 
out from the surface of UDG (white, center left) and inserts into the 
hydrophobic pocket on the otherwise negatively charged surface of 
Ugi (pink, center). This leucine-binding pocket is lined by a number 
of hydrophobic residues, including Met-124, Val-132, and Met-156. 
(C) The surface of the UDG is colored according to the electrostatic 
potential (-3 kT/e to +3 kT/e) as in (B). Ugi is shown as a red tube in the 
bound orientation observed in the human UDG-Ugi complex crystal 
structure. Key side chains of Ugi that interact with UDG are also shown 
(tubes colored green for hydrophobic and yellow for polar residues). 
The insertion of the Leu-272 side chain (white, centelr left) into the 
hydrophobic Ugi leucine-binding pocket and the extensive interactions 
that Ugi makes as it encompasses the UDG Leu-272 loop can be 
clearly seen. Figure displayed using standard and local modules of 
the AVS graphics system. 
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trates the DNA base stack and a flipped-out uracil base 
reaches into the uracil-binding pocket, DNA from the Hhal 
(cytosine-5)-methyltransferase-DNA complex crystal struc- 
ture (Klimasauskas et al., 1994) can be docked onto UDG 
(Figure 5). In this model complex, as proposed for HSV-1 
UDG (Savva et al., 1995), the long axis of the DNA helix 
is oriented essentially parallel to the positively charged 
UDG active site groove. The Leu-272 loop inserts into the 
DNA major groove, while the ~ helix connecting the third 
and fourth 13 strands of UDG directs its helix dipole toward 
the DNA minor groove. This model UDG-DNA complex, 
and the UDG-Ugi complex structure, suggest that the Ugi 
I~ sheet and ~2 structurally mimic the sugar-phosphate 
backbones of the DNA strands on either side of the UDG 
Leu-272 loop. With DNA bound in this orientation, the His- 
268 environment is not perturbed by DNA phosphate 
groups, and the extrahelical base from the methyltransfer- 
ase-DNA complex fits into the UDG active site. In fact, 
the uracil 3'-phosphate is in the same position as the Ugi 
Glu-120 carboxylate, and the uracil 5'-phosphate interacts 
with the Gin-144 side chain. 
In this model, the Leu-272 side chain penetrates the 
DNA base stack from the major groove, either passively 
occupying the space vacated by an extrahelical uracil or 
actively guiding the uracil into the uracil recognition pocket 
of the enzyme. Thus, the uracil could only flip out on the 
minor groove side of the DNA, as suggested for the Hhal 
methyltransferase (Klimasauskas et al., 1994). If actual 
"flipping out" of the uracil base is rate limiting, as sug- 
gested by the fact that the human, E. coli, and HSV-1 
enzymes all excise uracil more efficiently from UG mis- 
pairs than from UA pairs (Bennett et al., 1995; Verri et 
al., 1992), then the DNA sequence surrounding the uracil 
should influence the cleavage rate. Uracil accessibility to 
the active site pocket of the enzyme should decrease as 
the local melting of the DNA base stack decreases with 
increasing GC content. This is found for uracil excision 
by human UDG under conditions in which enzyme concen- 
tration is rate limiting. Uracil excision after 5 min incubation 
ranges from 100% for the 5' to 3' sequence CAUAA, to 
50% for CGUAA, falling to 25% for TGUGA, and finally 
only 5% for GGUGG (Slupphaug et al., 1995). Combined 
with the kinetics for UDG-Ugi complex formation (Bennett 
et al., 1993) and the structural information provided here, 
these sequence activity data suggest that UDG binding 
to both uracil-containing dsDNA and Ugi may be governed 
by the particular interactions urrounding Leu-272, either 
penetration into the DNA base stack or insertion into the 
leucine-binding pocket of Ugi. This may explain the spe- 
cific nature of the Ugi mimicry of the DNA substrate of 
UDG. 
Uracil in DNA is a rather subtle lesion, closely related 
to the naturally occurring DNA bases thymine, cytosine, 
and 5-methylcytosine. The recognition system developed 
for uracil detection may require actively probing the DNA 
by facilitating base expulsion rather than fortuitously bind- 
ing to a preexisting extrahelical uracil. A productive UDG- 
dsDNA complex can only be formed, however, if the 
flipped-out base is a uracil. No other naturally occurring 
base will fit into the recognition pocket of the enzyme (Mol 
Figure 5. Model for UDG Binding to Uracil-Containing dsDNA 
The UDG is shown as a Ca ribbon (purple) with key residue side chains 
from the UDG-Ugi interface depicted as colored tubes with positive 
(blue), polar (green), and hydrophobic (white). The DNA (red) is shown 
as a phosphate backbone ribbon with the individual nucleotides (tubes) 
and the extrahelical uracil base (thicker tubes). The DNA has been 
slightly bent about i s long axis using the local DNABENDER module 
(developed by T. J. Macke) for the AVS graphics ystem. (A) View of 
the proposed UDG-dsDNA complex with UDG in the same orientation 
as in Figure 3A. The DNA interacts with the same regions of UDG 
that interact with U gi in the complex. (B) View rotated - 90 °, illustrating 
the penetration f the side chain of Leu-272 into the DNA base stack 
via the major groove. 
et al., 1995; Savva et al., 1995). Thus, the side chain of 
Leu-272 will fully insert into the dsDNA base stack only 
when a uracil lesion has been detected. Full insertion of 
Leu-272 into the abasic site created by an extrahelical 
uracil can be expected to cause a certain amount of DNA 
bending, and the curvature and istribution of positively 
charged side chains around the UDG active site groove 
is able to accommodate this induced DNA bending (Fig- 
ures 4B and 5B). The resultant widening of the bent DNA 
major groove would allow deeper Leu-272 penetration and 
its movement oward the active site of the enzyme. Such 
movement of Leu-272 toward the active site is rigidly cou- 
pled to the proposed catalytic His-268 via the highly con- 
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served intervening residues Pro-269, Ser-270, and Pro- 
271. Thus, a productively bound f l ipped-out uracil base 
and a fully inserted Leu-272 side chain into the base stack 
of bent dsDNA may al low His-268 to move into catalytic 
posit ion for direct or general  base attack. 
Taken together,  the structural  results from the UDG-  
Ugi complex reveal that Ugi acts as a DNA mimic, suggest  
a more detai led model for UDG-DNA interactions, and 
provide the structural basis for the inhibition of an im- 
portant DNA repair enzyme. The design of new specif ic 
DNA repair inhibitors is of paramount  importance for im- 
proving the eff icacy and selectivity of current  chemo- and 
radiotherapies as well as for developing new antiviral strat- 
egies. 
Experimental Procedures 
UDG-Ugi Complex Formation 
The UDG-Ugi complex was formed by combining 0.5 i~mol of human 
UDG with 1.0 ~mol of Ugi and incubated at room temperature for 10 
min and at 4°C for an additional 20 rain. UDG-Ugi complex was puri- 
fied from excess Ugi by DE-52 cellulose column chromatography as 
previously described (Bennett and Mosbaugh, 1992), except that the 
equilibration buffer contained 30 mM Tris-HCI (pH 7.4), 1 mM EDTA, 
1 mM DTT, 50 mM NaCI, and 5% (w/v) glycerol. Complex was eluted 
stepwise by the addition of 120 ml of equilibration buffer containing 
125 mM NaCI. Fractions (4 ml) were analyzed by both 18% nondenatur- 
ing and 20% SDS-polyacrylamide gel electrophoresis to verify that 
complex was resolved from free UDG and Ugi (Bennett and Mosbaugh, 
1992). Peak fractions of UDG-Ugi were pooled, concentrated -32- 
fold to - 1 ml, and diafiltrated into equilibration buffer without NaCI 
using an Amicon stirred cell (YM10 membrane). Following the concen- 
tration step, the UDG-Ugi complex (A280om = 10.8) was determined 
to contain 170 I~M protein by absorbance spectroscopy using the molar 
extinction.coefficient E280nm = 6.3 x 104 calculated from the sum of 
the extinction coefficients of UDG (Figure 1) and Ugi (E280 ~ = 
1.2 x 104). 
Crystallization and Data Collection 
The cloning, expression, and purification of human UDG have been 
described previously (Olsen et al., 1989; Stupphaug et al., 1995; Mol 
et al., 1995). UDG refers to the enzyme from human and nonbacterial 
systems. The human UDG used here represents an active recombi- 
nant protein (UNGA84), in which the N-terminal 84 amino acids en- 
coded by the human UNG gene have been replaced by three amino 
acids from the vector. The E. coil UDG counterpart (Ung) is encoded 
by the ung gene. The cloning and expression of the bacteriophage 
PBS2 Ugi protein are described elsewhere (Wang and Mosbaugh, 
1988; Wang et al. 1991). 
Crystals of the human UDG-Ugi complex were grown by the hang- 
ing drop vapor diffusion technique by mixing equal volumes of the 
protein solution (15 mg/ml) with reservoir solutions containing 20% 
polyethylene glycol 4000 (Sigma) and 100 mM imidazole/maleate 
buffer (pH 5.0). The crystals are monoclinic P2, (a = 48.3 ,~, b = 
64.5 ~,,c = 55.2 ~,, and !3 = 113.8 °) and contain one U DG-Ugi complex 
per crystallographic asymmetric unit. These crystals have a VM (Mat- 
thews, 1968) of 2.3, which is within the range observed for other protein 
crystals. 
X-ray diffraction data for all crystals were collected at room tempera- 
ture using a 30 cm MAR research imaging plate and an oscillation 
width of 1.0 ° per frame. Native data were collected at a wavelength 
of 1.08/~ on beam line 7-1 of the Stanford Synchrotron Radiation Labo- 
ratory (SSRL) and were processed using the program DENZO (Otwi- 
nowski, 1993). Heavy atom derivative data were collected at a wave- 
length of 1.54 ~, using a Rigaku rotating anode X-ray generator operating 
at 50 kV and 100 mA with a typical exposu re time of 15 min per frame. 
These data were processed using the program MARXDS (Kabsch, 
1988). Heavy atom positions were determined from isomorphous dif- 
ference Patterson maps and cross-difference Fourier maps using the 
XtalView program suite (McRee, 1992), and by analogy to the same 
heavy atom-binding sites determined for the structure of uncomplexed 
human UDG (Mol et al., 1995). The heavy atom positions and occupan- 
cies were refined and MIR map coefficients calculated using XtalView. 
Molecular Replacement 
Molecular replacement calculations were performed with X-PLOR 
(Br0nger et al., 1987) version 3.1, using as a model the structure of 
uncomplexed UDG (Mol et al., 1995) refined to 1.57 ,~ resolution with 
a crystallographic R value of 0.197 (30,530 reflections, R%e = 0.255) 
with rms deviations of the bond lengths and angles of 0.020 A and 3.1 o 
respectively. Rotation function calculations were performed using all 
data (5,369 reflections) in the resolution range 3.0-6.0 ,g,. The uncom- 
plexed UDG search model was placed in a P1 box of dimensions 
128.0 x 128.0 x 128.0 ,~, and the maximum Patterson search vector 
was set to 35.0 P,. The correct rotation peak was at a height of 14.6a 
above the mean with the highest background peak at a height of 3.9~ 
above the mean. This rotation peak gave a correlation factor of 0.31 
after Patterson co rrelation refinement (BrLinger et al., 1987). The trans- 
lation search was carried out in the Y = 0.0 plane using the oriented 
model and data between 3.0 and 6.0 ,~ resolution. The correct ransla- 
tion peak was 9.8o above the mean, with the highest background peak 
at a height of 2.4~ above the mean. 
Model Building and Refinement 
The correctly oriented and positioned UDG model was subjected to 
Powell conjugate-gradient energy minimization using X-PLOR (Bren- 
ger et al., 1987) yielding an initial crystallographic R value of 0.281 
for 9,480 reflections in the resolution range 2.5-6.0/~,. The value of 
Rfree (Brenger, 1992) for 5% of reflections against which the model 
was not refined was 0.422. This model was used to calculate phases 
that were combined with the MIR phases using the program OAo(Read, 
1986) to produce combined phase maps at a resolution of 2.5 A. Elec- 
tron density for portions of Ugi that were close to UDG, notably 131 
and a2, were clearly visible in these phase-combined electron density 
maps, and the amino acid sequence was fit to the density. This partial 
model of Ugi was then refined along with the model for UDG and used 
to calculate new phases. Cycles of model building, refinement, and 
phase combination with ~A were used until the entire sequence of Ugi 
from residues 3-84 had been placed. 
This complete model for the human UDG-Ugi complex was refined 
using stereochemically restrained simulated annealing and positional 
refinement with X-PLOR. Rounds of refinement, gradually including 
the high resolution data to 1.9 ,~ resolution, were interspersed with 
manual inspection and rebuilding of the structure using the interactive 
graphics program XFIT (McRee, 1992). The model was inspected us- 
ing ~A-weighted Fo - Fc and 2Fo - Fo electron density maps, as well 
as simulated-annealed omit maps in which 20 residue stretches of the 
model had been omitted from the phase calculation. Ordered solvent 
molecules were manually placed at the appropriate positions of Fo - 
Fc electron density maps and included in the refinement at higher 
resolutions. Individual atomic temperature values were applied to all 
atoms, and an overall anisotropic temperature factor correction was 
applied to the native data set. Progress was monitored throughout he 
course of refinement and manual rebuilding of the model by monitoring 
the consistent decrease in the values of both the conventional crystallo- 
graphic R value and the free R value. 
The human UDG-Ugi complex structure contains 2455 nonhydro- 
gen protein atoms and 267 ordered solvent molecules and has been 
refined to an R value of 0.197 for 19,407 reflections in the resolution 
range 8.0-1.9 ,~, with F > 3.0 OF. The corresponding value for the free 
R is 0.282 for 5% of reflections against which the model was not 
refined. The rms deviations from ideality of the bond lengths is 0.018 
,g,, the bond angles 3.47 °, the dihedral angles 25.7 °, and the improper 
angles 1.56 °, 
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